Gilead Sciences (GILD) EBITDA Margin (2009 - 2026)
Gilead Sciences' (GILD) quarterly EBITDA Margin came in at 37.16% in Q1 2026, up 360.0% YoY from 8.08% in Q1 2025, and up 48.41% on a QoQ basis from 25.03% in Q4 2025.
Gilead Sciences (GILD) EBITDA Margin (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of EBITDA Margin data on file, last reported at 37.16% in Q1 2026.
- Quarterly EBITDA Margin rose 360.0% year-over-year to 37.16% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34.88% (up 627.0% YoY) and the FY2025 annual result came in at 34.04%, up 2826.0% from the prior year.
- EBITDA Margin rose to 37.16% in Q1 2026, from 25.03% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 42.82% in Q3 2025 to a low of 64.64% in Q1 2024.
- A 5-year average of 24.08% and a median of 32.4% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2024 — EBITDA Margin sank 9148 bps — and 2025, when it soared 9820 bps.
- Tracing GILD's EBITDA Margin over 5 years: stood at 30.68% in 2022, then decreased by 26 bps to 22.66% in 2023, then surged by 43 bps to 32.4% in 2024, then dropped by 23 bps to 25.03% in 2025, then jumped by 48 bps to 37.16% in 2026.
- The last three EBITDA Margin figures came in at 37.16% (Q1 2026), 25.03% (Q4 2025), and 42.82% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 28.37% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 5.72% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 124.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -133.21% |
| Mar 31, 2026 | 37.16% |
| Dec 31, 2025 | 25.03% |
| Sep 30, 2025 | 42.82% |
| Jun 30, 2025 | 34.93% |
| Mar 31, 2025 | 33.55% |
| Dec 31, 2024 | 32.40% |
| Sep 30, 2024 | 11.77% |
| Jun 30, 2024 | 38.02% |
| Mar 31, 2024 | -64.64% |
| Dec 31, 2023 | 22.66% |
| Sep 30, 2023 | 37.20% |
| Jun 30, 2023 | 25.23% |
| Mar 31, 2023 | 26.84% |
| Dec 31, 2022 | 30.68% |
| Sep 30, 2022 | 40.29% |
| Jun 30, 2022 | 32.41% |
| Mar 31, 2022 | 2.99% |
| Dec 31, 2021 | 12.98% |
| Sep 30, 2021 | 51.77% |